News
ESSA Pharma Announces Pricing of Public Offering of Common Shares
ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
ESSA Pharma to Present at Jefferies Virtual Healthcare Conference
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
ESSA Pharma Inc. Reports Results of Annual General & Special Meeting of Shareholders
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 21, 2019